Drug makers reportedly cut deal with FDA on fees (Boston Globe)
Drug makers agreed to a 29 percent increase in payments to U S regulators to ensure speedy approvals of new medicines and step up safety monitoring, according to a person familiar with the accord.

Repligen Receives Orphan Drug Designation From The FDA For RG1068 For MRI Imaging Of The Pancreas (Medical News Today)
Repligen Corporation (Nasdaq: RGEN) announced today that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) granted orphan drug designation to RG1068, synthetic human secretin, for use with magnetic resonance imaging (MRI) of the pancreas. [click link for full article]